Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

BURU vs IPGP vs LYRA vs NPKI vs MKSI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BURU
Nuburu, Inc.

Industrial - Machinery

IndustrialsAMEX • US
Market Cap$1M
5Y Perf.-89.8%
IPGP
IPG Photonics Corporation

Semiconductors

TechnologyNASDAQ • US
Market Cap$4.31B
5Y Perf.+30.2%
LYRA
Lyra Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$781K
5Y Perf.-90.3%
NPKI
NPK International Inc.

Oil & Gas Equipment & Services

EnergyNYSE • US
Market Cap$1.30B
5Y Perf.+84.6%
MKSI
MKS Inc.

Hardware, Equipment & Parts

TechnologyNASDAQ • US
Market Cap$20.25B
5Y Perf.+164.7%

BURU vs IPGP vs LYRA vs NPKI vs MKSI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BURU logoBURU
IPGP logoIPGP
LYRA logoLYRA
NPKI logoNPKI
MKSI logoMKSI
IndustryIndustrial - MachinerySemiconductorsBiotechnologyOil & Gas Equipment & ServicesHardware, Equipment & Parts
Market Cap$1M$4.31B$781K$1.30B$20.25B
Revenue (TTM)$109K$1.04B$600K$287M$4.07B
Net Income (TTM)$-63M$29M$-33M$36M$327M
Gross Margin-392.0%37.6%50.0%35.2%45.2%
Operating Margin-116.1%0.3%-58.2%11.4%14.8%
Forward P/E62.6x29.3x30.4x
Total Debt$9M$0.00$34M$37M$4.69B
Cash & Equiv.$209K$404M$41M$5M$675M

BURU vs IPGP vs LYRA vs NPKI vs MKSILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BURU
IPGP
LYRA
NPKI
MKSI
StockNov 24May 26Return
Nuburu, Inc. (BURU)10010.2-89.8%
IPG Photonics Corpo… (IPGP)100130.2+30.2%
Lyra Therapeutics, … (LYRA)1009.7-90.3%
NPK International I… (NPKI)100184.6+84.6%
MKS Inc. (MKSI)100264.7+164.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: BURU vs IPGP vs LYRA vs NPKI vs MKSI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NPKI leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. MKS Inc. is the stronger pick specifically for dividend income and shareholder returns and recent price momentum and sentiment. LYRA also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
BURU
Nuburu, Inc.
The Industrials Pick

BURU lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: industrials exposure
IPGP
IPG Photonics Corporation
The Income Pick

IPGP is the clearest fit if your priority is income & stability.

  • Dividend streak 1 yrs, beta 1.80
Best for: income & stability
LYRA
Lyra Therapeutics, Inc.
The Defensive Pick

LYRA ranks third and is worth considering specifically for sleep-well-at-night and defensive.

  • Lower volatility, beta 0.65, current ratio 3.41x
  • Beta 0.65, current ratio 3.41x
  • Beta 0.65 vs MKSI's 2.64
Best for: sleep-well-at-night and defensive
NPKI
NPK International Inc.
The Growth Play

NPKI carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth 27.4%, EPS growth 124.0%, 3Y rev CAGR 12.8%
  • 27.4% revenue growth vs BURU's -92.7%
  • Better valuation composite
  • 12.4% margin vs BURU's -578.5%
Best for: growth exposure
MKSI
MKS Inc.
The Long-Run Compounder

MKSI is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 7.5% 10Y total return vs NPKI's 91.5%
  • 0.3% yield; the other 4 pay no meaningful dividend
  • +306.1% vs LYRA's -91.6%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNPKI logoNPKI27.4% revenue growth vs BURU's -92.7%
ValueNPKI logoNPKIBetter valuation composite
Quality / MarginsNPKI logoNPKI12.4% margin vs BURU's -578.5%
Stability / SafetyLYRA logoLYRABeta 0.65 vs MKSI's 2.64
DividendsMKSI logoMKSI0.3% yield; the other 4 pay no meaningful dividend
Momentum (1Y)MKSI logoMKSI+306.1% vs LYRA's -91.6%
Efficiency (ROA)NPKI logoNPKI8.5% ROA vs BURU's -479.1%

BURU vs IPGP vs LYRA vs NPKI vs MKSI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BURUNuburu, Inc.

Segment breakdown not available.

IPGPIPG Photonics Corporation
FY 2025
High Power Continuous Wave CW Lasers
41.8%$309M
Laser And Non-Laser Systems
19.9%$147M
Pulsed Lasers
19.4%$143M
Medium And Low Power CW Lasers
11.9%$88M
Quasi-Continuous Wave QCW Lasers
7.0%$52M
LYRALyra Therapeutics, Inc.

Segment breakdown not available.

NPKINPK International Inc.
FY 2025
Rental and Service
66.3%$184M
Product
33.7%$93M
MKSIMKS Inc.
FY 2025
Product
87.4%$3.4B
Service
12.6%$495M

BURU vs IPGP vs LYRA vs NPKI vs MKSI — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLNPKILAGGINGLYRA

Income & Cash Flow (Last 12 Months)

NPKI leads this category, winning 2 of 6 comparable metrics.

MKSI is the larger business by revenue, generating $4.1B annually — 37388.0x BURU's $108,912. NPKI is the more profitable business, keeping 12.4% of every revenue dollar as net income compared to BURU's -578.5%. On growth, IPGP holds the edge at +16.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBURU logoBURUNuburu, Inc.IPGP logoIPGPIPG Photonics Cor…LYRA logoLYRALyra Therapeutics…NPKI logoNPKINPK International…MKSI logoMKSIMKS Inc.
RevenueTrailing 12 months$108,912$1.0B$600,000$287M$4.1B
EBITDAEarnings before interest/tax-$39M$55M-$34M$53M$945M
Net IncomeAfter-tax profit-$63M$29M-$33M$36M$327M
Free Cash FlowCash after capex-$8M$8M-$34M$32M$401M
Gross MarginGross profit ÷ Revenue-3.9%+37.6%+50.0%+35.2%+45.2%
Operating MarginEBIT ÷ Revenue-116.1%+0.3%-58.2%+11.4%+14.8%
Net MarginNet income ÷ Revenue-578.5%+2.8%-54.9%+12.4%+8.0%
FCF MarginFCF ÷ Revenue-69.8%+0.8%-56.8%+11.1%+9.8%
Rev. Growth (YoY)Latest quarter vs prior year+16.6%-87.2%+15.9%+15.2%
EPS Growth (YoY)Latest quarter vs prior year+82.1%-54.4%-17.8%0.0%+53.2%
NPKI leads this category, winning 2 of 6 comparable metrics.

Valuation Metrics

Evenly matched — LYRA and NPKI each lead in 2 of 6 comparable metrics.

At 36.8x trailing earnings, NPKI trades at a 74% valuation discount to IPGP's 139.2x P/E. On an enterprise value basis, NPKI's 18.5x EV/EBITDA is more attractive than IPGP's 48.9x.

MetricBURU logoBURUNuburu, Inc.IPGP logoIPGPIPG Photonics Cor…LYRA logoLYRALyra Therapeutics…NPKI logoNPKINPK International…MKSI logoMKSIMKS Inc.
Market CapShares × price$1M$4.3B$781,126$1.3B$20.2B
Enterprise ValueMkt cap + debt − cash$11M$3.9B-$5M$1.3B$24.3B
Trailing P/EPrice ÷ TTM EPS-0.04x139.22x-0.31x36.75x68.83x
Forward P/EPrice ÷ next-FY EPS est.62.62x29.34x30.36x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple48.90x18.49x26.70x
Price / SalesMarket cap ÷ Revenue9.14x4.30x0.51x4.71x5.15x
Price / BookPrice ÷ Book value/share2.04x2.47x3.77x7.49x
Price / FCFMarket cap ÷ FCF49.58x40.74x
Evenly matched — LYRA and NPKI each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

NPKI leads this category, winning 6 of 9 comparable metrics.

MKSI delivers a 12.2% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-10 for LYRA. NPKI carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to LYRA's 2.97x. On the Piotroski fundamental quality scale (0–9), NPKI scores 7/9 vs BURU's 1/9, reflecting strong financial health.

MetricBURU logoBURUNuburu, Inc.IPGP logoIPGPIPG Photonics Cor…LYRA logoLYRALyra Therapeutics…NPKI logoNPKINPK International…MKSI logoMKSIMKS Inc.
ROE (TTM)Return on equity+1.4%-10.3%+10.3%+12.2%
ROA (TTM)Return on assets-4.8%+1.2%-60.2%+8.5%+3.7%
ROICReturn on invested capital+0.6%-145.5%+9.9%+6.5%
ROCEReturn on capital employed+0.6%-109.0%+12.7%+7.2%
Piotroski ScoreFundamental quality 0–916276
Debt / EquityFinancial leverage2.97x0.10x1.73x
Net DebtTotal debt minus cash$9M-$404M-$6M$31M$4.0B
Cash & Equiv.Liquid assets$209,337$404M$41M$5M$675M
Total DebtShort + long-term debt$9M$0$34M$37M$4.7B
Interest CoverageEBIT ÷ Interest expense-4.34x77.08x2.84x
NPKI leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MKSI leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in NPKI five years ago would be worth $19,150 today (with dividends reinvested), compared to $6 for BURU. Over the past 12 months, MKSI leads with a +306.1% total return vs LYRA's -91.6%. The 3-year compound annual growth rate (CAGR) favors MKSI at 54.1% vs BURU's -89.2% — a key indicator of consistent wealth creation.

MetricBURU logoBURUNuburu, Inc.IPGP logoIPGPIPG Photonics Cor…LYRA logoLYRALyra Therapeutics…NPKI logoNPKINPK International…MKSI logoMKSIMKS Inc.
YTD ReturnYear-to-date-76.1%+35.8%-86.1%+27.6%+78.8%
1-Year ReturnPast 12 months-65.9%+75.6%-91.6%+94.9%+306.1%
3-Year ReturnCumulative with dividends-99.9%-12.7%-99.7%+91.5%+266.0%
5-Year ReturnCumulative with dividends-99.9%-48.5%-99.9%+91.5%+66.5%
10-Year ReturnCumulative with dividends-99.9%+20.2%-100.0%+91.5%+750.6%
CAGR (3Y)Annualised 3-year return-89.2%-4.4%-85.0%+24.2%+54.1%
MKSI leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LYRA and NPKI each lead in 1 of 2 comparable metrics.

LYRA is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than MKSI's 2.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NPKI currently trades 93.5% from its 52-week high vs LYRA's 1.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBURU logoBURUNuburu, Inc.IPGP logoIPGPIPG Photonics Cor…LYRA logoLYRALyra Therapeutics…NPKI logoNPKINPK International…MKSI logoMKSIMKS Inc.
Beta (5Y)Sensitivity to S&P 5001.21x1.80x0.65x1.47x2.64x
52-Week HighHighest price in past year$4.24$155.82$37.50$16.50$326.83
52-Week LowLowest price in past year$0.15$53.98$0.44$7.63$71.49
% of 52W HighCurrent price vs 52-week peak+5.6%+65.2%+1.2%+93.5%+92.0%
RSI (14)Momentum oscillator 0–10047.739.722.356.665.3
Avg Volume (50D)Average daily shares traded41.8M510K159K795K1.2M
Evenly matched — LYRA and NPKI each lead in 1 of 2 comparable metrics.

Analyst Outlook

IPGP leads this category, winning 1 of 1 comparable metric.

Analyst consensus: IPGP as "Buy", NPKI as "Buy", MKSI as "Buy". Consensus price targets imply 49.2% upside for IPGP (target: $152) vs -9.3% for MKSI (target: $273). MKSI is the only dividend payer here at 0.29% yield — a key consideration for income-focused portfolios.

MetricBURU logoBURUNuburu, Inc.IPGP logoIPGPIPG Photonics Cor…LYRA logoLYRALyra Therapeutics…NPKI logoNPKINPK International…MKSI logoMKSIMKS Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$151.67$272.86
# AnalystsCovering analysts27329
Dividend YieldAnnual dividend ÷ price+0.3%
Dividend StreakConsecutive years of raises100
Dividend / ShareAnnual DPS$0.87
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.3%0.0%+1.7%+0.2%
IPGP leads this category, winning 1 of 1 comparable metric.
Key Takeaway

NPKI leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MKSI leads in 1 (Total Returns). 2 tied.

Best OverallNPK International Inc. (NPKI)Leads 2 of 6 categories
Loading custom metrics...

BURU vs IPGP vs LYRA vs NPKI vs MKSI: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BURU or IPGP or LYRA or NPKI or MKSI a better buy right now?

For growth investors, NPK International Inc.

(NPKI) is the stronger pick with 27. 4% revenue growth year-over-year, versus -92. 7% for Nuburu, Inc. (BURU). NPK International Inc. (NPKI) offers the better valuation at 36. 8x trailing P/E (29. 3x forward), making it the more compelling value choice. Analysts rate IPG Photonics Corporation (IPGP) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BURU or IPGP or LYRA or NPKI or MKSI?

On trailing P/E, NPK International Inc.

(NPKI) is the cheapest at 36. 8x versus IPG Photonics Corporation at 139. 2x. On forward P/E, NPK International Inc. is actually cheaper at 29. 3x.

03

Which is the better long-term investment — BURU or IPGP or LYRA or NPKI or MKSI?

Over the past 5 years, NPK International Inc.

(NPKI) delivered a total return of +91. 5%, compared to -99. 9% for Nuburu, Inc. (BURU). Over 10 years, the gap is even starker: MKSI returned +750. 6% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BURU or IPGP or LYRA or NPKI or MKSI?

By beta (market sensitivity over 5 years), Lyra Therapeutics, Inc.

(LYRA) is the lower-risk stock at 0. 65β versus MKS Inc. 's 2. 64β — meaning MKSI is approximately 309% more volatile than LYRA relative to the S&P 500. On balance sheet safety, NPK International Inc. (NPKI) carries a lower debt/equity ratio of 10% versus 3% for Lyra Therapeutics, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — BURU or IPGP or LYRA or NPKI or MKSI?

By revenue growth (latest reported year), NPK International Inc.

(NPKI) is pulling ahead at 27. 4% versus -92. 7% for Nuburu, Inc. (BURU). On earnings-per-share growth, the picture is similar: NPK International Inc. grew EPS 124. 0% year-over-year, compared to -13. 5% for Lyra Therapeutics, Inc.. Over a 3-year CAGR, LYRA leads at 75. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BURU or IPGP or LYRA or NPKI or MKSI?

NPK International Inc.

(NPKI) is the more profitable company, earning 13. 0% net margin versus -226. 9% for Nuburu, Inc. — meaning it keeps 13. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NPKI leads at 16. 9% versus -86. 4% for BURU. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BURU or IPGP or LYRA or NPKI or MKSI more undervalued right now?

On forward earnings alone, NPK International Inc.

(NPKI) trades at 29. 3x forward P/E versus 62. 6x for IPG Photonics Corporation — 33. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IPGP: 49. 2% to $151. 67.

08

Which pays a better dividend — BURU or IPGP or LYRA or NPKI or MKSI?

In this comparison, MKSI (0.

3% yield) pays a dividend. BURU, IPGP, LYRA, NPKI do not pay a meaningful dividend and should not be held primarily for income.

09

Is BURU or IPGP or LYRA or NPKI or MKSI better for a retirement portfolio?

For long-horizon retirement investors, Lyra Therapeutics, Inc.

(LYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). IPG Photonics Corporation (IPGP) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LYRA: -100. 0%, IPGP: +20. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BURU and IPGP and LYRA and NPKI and MKSI?

These companies operate in different sectors (BURU (Industrials) and IPGP (Technology) and LYRA (Healthcare) and NPKI (Energy) and MKSI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BURU is a small-cap quality compounder stock; IPGP is a small-cap quality compounder stock; LYRA is a small-cap quality compounder stock; NPKI is a small-cap high-growth stock; MKSI is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

BURU

Quality Business

  • Sector: Industrials
  • Market Cap > $100B
Run This Screen
Stocks Like

IPGP

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 8%
  • Gross Margin > 22%
Run This Screen
Stocks Like

LYRA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 30%
Run This Screen
Stocks Like

NPKI

High-Growth Compounder

  • Sector: Energy
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 7%
Run This Screen
Stocks Like

MKSI

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform BURU and IPGP and LYRA and NPKI and MKSI on the metrics below

Revenue Growth>
%
(BURU: -92.7% · IPGP: 16.6%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.